Clinical Trials Logo
  1. Home
  2. Rotavirus Infections
  3. NCT05037435

Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.

Rotavirus Infections Clinical Trial

Official title:
Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study of the Safety and Efficacy of the Vaccine for the Prevention of Pentavalent Live Rotavirus Infection in Healthy Subjects (Target Age of 18-45 Years Old).

Clinical Trial Summary

The purpose of the presented study was to evaluate the safety and immunological efficacy in preventing the rotavirus infection within a cohort of healthy subjects (target age of 18-45 years old) by using the pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried).

Clinical Trial Description

The clinical study named "Prospective, randomized, double-blind, placebo-controlled study of safety and immunological efficacy for preventing a rotavirus infection pentavalent vaccine, live attenuated at the healthy subjects at the age of 18-45 years" was conducted in the Russian Federation. The mentioned study was performed as per Protocol of clinical trial No. RTB 001/18 (given by MOH RF exp June 7, 2018). All relevant requirements of the National Legislative system and the international rules of conduct of clinical trials (ICH GCP). The study objective was to assess the safety and immunological efficacy for preventing a rotavirus infection pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried) at healthy adults aged 18 to 45 years for the subsequent vaccination of the children's contingent. For the achievement of a goal, it was necessary to solve the following problems: 1. Assessment of the vaccine's safety for preventing a rotavirus infection pentavalent live compared to placebo at a single oral introduction to volunteers at the age of 18-45 years. 2. Immunological efficacy assessment for prevention of a rotavirus infection pentavalent live in comparison with placebo at a single oral introduction to volunteers at the age of 18-45 years ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05037435
Study type Interventional
Source Limited Liability Company Pharm Aid
Contact
Status Completed
Phase Phase 3
Start date June 25, 2018
Completion date July 27, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT02220439 - Does the Fecal Microbiome Influence Rotarix Immunogenicity N/A
Withdrawn NCT00757926 - Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants Phase 1/Phase 2
Not yet recruiting NCT00484952 - Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel N/A
Completed NCT00092443 - Dose Confirmation Efficacy Study (V260-007) Phase 3
Terminated NCT01357174 - ROTATEQ™ Post-Marketing Surveillance in the Philippines N/A
Recruiting NCT01363726 - Surveillance of Rotavirus Gastroenteritis in Children <5 Years N/A
Completed NCT00130832 - Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) Phase 3
Recruiting NCT06080906 - Phase II Clinical Trial of the Inactivated Rotavirus Vaccine Phase 2
Recruiting NCT03313128 - SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance
Completed NCT02542462 - Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study Phase 4
Completed NCT00346892 - To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV Phase 2
Not yet recruiting NCT05212935 - A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
Completed NCT00092456 - Consistency Lots Vaccine Study (V260-009) Phase 3
Completed NCT00981669 - Rotavirus Vaccine Produced by Butantan Institute Phase 1
Completed NCT03483116 - A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Phase 2
Completed NCT03870061 - Evaluation of an Infant Immunization Encouragement Program in Nigeria N/A
Active, not recruiting NCT05621655 - Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers Phase 2
Completed NCT00280111 - Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants Phase 1
Completed NCT00090233 - Rotavirus Efficacy and Safety Trial (REST)(V260-006) Phase 3